Ann: Phase 2 Stroke Clinical Trial Update, page-29

After reviewing the numbers post-presentation, I'm trying to make sense of the potential upside, and frankly, it's a bit overwhelming. I'd appreciate it if some experts could confirm this, as I might be missing something. It is making me dizzy lol

Dr. Liz mentioned the potential price per dose of ARG-007 could range from $10,000 to $20,000 USD, with an average assumption of $15,000 USD per dose.
Considering there are over 7.6 million new ischemic strokes annually worldwide, and approximately 62% of all incident strokes are ischemic strokes (source: World Stroke Organization), I conservatively estimate that about 5% of these cases could benefit from ARG-007, which totals roughly 360,000 patients per year.

Using the average price assumption:

1. Potential revenue: $15,000 x 360,000 = $5.4 billion USD (approximately $8 billion AUD) annually from stroke indications alone.
2. If the price per treatment reaches $20,000 USDotential revenue increases to $7.2 billion USD (approximately $10 billion AUD) annually from stroke indications alone

• This represents a potential multiple of 100 times from current prices if the drug proves successful. Could anyone confirm if my understanding is correct?